About

ReViral has a team of experienced executives, managers and scientists who work closely with key collaborators and consultants to combine expertise in the areas of virology and antiviral therapies

  • ReViral was founded in 2011 by members of the highly successful Arrow Therapeutics team, led by Dr Ken Powell as CEO and Dr Stuart Cockerill as CSO
  • The team has a track record in the development of compounds with activity against RSV
  • Professor Raymond Schinazi joined the ReViral board in 2014
  • In 2015 ReViral announced US$21 million fundraising to advance clinical development of a novel anti-viral drugs
  • In October 2016 ReViral announced the appointment of Dr Eddy Littler as Chief Executive Officer
  • In 2017, ReViral announced top-line safety and pharmacokinetics for RSV antiviral RV-521 in Healthy Volunteers
  • In 2018 RV521 completed a phase 2a in adult volunteers showing high potency and excellent safety
Board of Directors
Dr Ken Powell - Chairman

Prior to his current role, Ken had very extensive experience of the Biotechnology sector. In reverse order he was: Executive Chairman of Q-Chip a Cardiff, Wales based life science company developing novel delayed release formulations of drugs (merged with Midatech and the joint company listed on AIM in 2015). Founder and CEO of Arrow Therapeutics Ltd (a specialised antiviral drug discovery company acquired by Astra-Zeneca PLC for $150 million in February 2007). Professor at UCL and Deputy Director of the Wolfson Institute for Biomedical Research where he had responsibility for commercial activity including setting up five biotechnology start-up companies. He was a senior Pharmaceutical executive with the Wellcome Foundation which he decided to leave at the Wellcome/Glaxo merger. He has had a successful academic career in the UK and USA.

He is an expert virologist and has been involved in the development of multiple drugs including anti-viral compounds against herpes viruses, HIV, Hepatitis C and RSV.

 

Dr Eddy Littler - Chief Executive Officer

Eddy began his research career at the University of Leeds studying herpesvirus DNA replication. After postdoctoral research at McMaster University in Canada, he joined the Paterson Institute for Cancer Research in Manchester. Here Eddy investigated viruses and cancer including Epstein-Barr virus and Human Herpesvirus type 6. After six successful years, he joined the Wellcome Research Laboratories as Head of Herpes Virus Research. During his time at Wellcome, he became Head of the Gene Targets Group which had projects in herpesviruses, respiratory viruses, including RSV, and gene therapy of ovarian cancer. Following the acquisition of Wellcome by Glaxo he became Head of Antiviral Research at GlaxoWellcome leading teams working on hepatitis C virus, influenza virus, and respiratory syncytial virus.  

Eddy left GSK in 2000 to join Medivir as Senior Director of Lead Discovery and Head of UK Operations. While at Medivir he played a significant role in several deals, including the development and eventual out-licensing of the HCV protease inhibitor (Simeprevir) programme to Tibotec (J&J). The total value of transactions converted at Medivir was $360M.

Eddy became the Chief Executive Officer of Domainex in May 2008. He developed Domainex to become one of the UKs leading drug discovery CROs. Under his leadership, Domainex also developed a pipeline of drugs aimed at inflammation and cancer. In October 2016 Eddy joined ReViral as CEO.

Dr. Raymond F. Schinazi - Non-Executive Director

Dr. Raymond F. Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University and co-Director of the HIV Cure Scientific Working Group for the NIH-sponsored Emory University CFAR. A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV and hepatitis C virus (HCV) drugs d4T (stavudine), 3TC (lamivudine), FTC (emtricitabine/Emtriva), LdT (telbivudine) and sofosbuvir (Sovaldi), which are all approved by the US FDA. Fixed dose combination of these drugs has resulted in 16 NDAs. Furthermore, over 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented. He is also the founder of five biotechnology companies, including Pharmasset, Inc. (VRUS; acquired by Gilead in 2012 for $11.4 B).

Dr. Schinazi served on the Presidential Commission on AIDS and is the recipient of numerous awards, including the 2015 William S. Middleton Award from the Department of Veterans Affairs, which is the highest honor for outstanding achievement in biomedical research; the 2016 Institute of Human Virology’s Lifetime Achievement Award for Public Service; 2016 Scrip Lifetime Achievement Award; 2017 Excellence Prize from Journées Québécoises, McGill University; and State of the Art Award from the 2017 Paris Hepatology Conference. Dr. Schinazi currently serves as a governing trustee for the Foundation for AIDS research (amfAR). He also serves on the board of directors of the International Centre for Missing and Exploited Children (ICMEC) as well as the Global Virus Network (GVN) where he is a member of GVN’s Executive Committee. Most recently he was appointed as a Senior Advisor to the International Coalition to Eliminate HBV (ICE-HBV). Dr. Schinazi is internationally recognized as one of the most influential persons in the life science sector.

Raphaël Wisniewski - Partner, Andera Partners

Raphaël began his career in London, where he spent seven years in the healthcare and investment banking industries. He was first part of the finance department of Générale de Santé International in London, the largest private hospitals group in the UK, where he held treasury and investment analysis functions. He subsequently worked in the healthcare groups of the Investment Banking divisions of Salomon Smith Barney (1996-1999) and Goldman Sachs (1999-2001) where he participated in many M&A and capital raising deals within pharmaceuticals, medical devices, biotechnology and services companies. Since joining EdRIP in 2001 he has worked on several investments, IPOs and trade sales in the biotechnology and medical device sectors. He currently sits on the boards of Cellnovo Group, Poxel, Genticel, Implanet, Chase Pharmaceuticals and Axonics.

Raphaël graduated from the French business school HEC in 1993 and received a Masters in Applied Economics from Institut d'Etudes Politiques in 1994.

Chau Q. Khuong - Private Equity Partner, OrbiMed

Chau joined OrbiMed Advisors in 2003 and is a Private Equity Partner focused on structured investments in private and public biopharmaceutical and medical device companies.  Mr. Khuong has been extensively involved with development and commercial stage companies in multiple therapeutic areas from cancer to anti-infectives to liver diseases and ophthalmology.  He is currently a Board Director or Observer at Aerpio (NASDAQ: ARPO), Graybug Vision, Inspire Medical Systems (NYSE: INSP), Kandy, Nerre, and Synlogic (NASDAQ: SYBX).  

Prior to OrbiMed, Mr. Khuong worked in start-up operations and business development at Veritas Medicine and also has experience in basic science research at Yale School of Medicine and Massachusetts General Hospital. Mr. Khuong holds a BS (Molecular Biology) and an MPH (Infectious Diseases) from Yale University.

Isaac Manke - General Partner, New Leaf

Isaac Manke is a General Partner at New Leaf Venture Partners and concentrates on biopharmaceutical investments. Isaac joined New Leaf in 2009 as an Associate and became a Partner in 2014. Prior to joining New Leaf, Isaac was an Associate in the Global Biotechnology Equity Research group at Sanford C. Bernstein. Previously, Isaac worked as an Associate in the Biotechnology Equity Research group at Deutsche Bank and was a Senior Analyst at Health Advances, a biopharmaceutical and medical device strategy consulting firm. Isaac received a B.A. in Biology and a B.A. in Chemistry at Minnesota State University (Moorhead), and a Ph.D. in Biophysical Chemistry and Molecular Structure at the Massachusetts Institute of Technology (MIT). Isaac’s discoveries led to several publications in top journals, including Science and Cell, and were selected by Science as one of the “2003: Signaling Breakthroughs of the Year”. These discoveries also resulted in four issued patents.

Nanna Lüneborg - Partner, Novo Ventures

Nanna joined Novo Holdings in 2012, and spent four years as part of Novo Seeds, where she helped build a strong portfolio of seed and Series A stage companies, primarily in Scandinavia. She led the initial investments and served on the Boards as Director or Observer at Inthera, IO Biotech, MinervaX, Pcovery, Forendo and Galecto. Nanna joined Novo Ventures in 2016, and has been involved in both private and public investments, including successful public listings of Orphazyme (ORPHA) and ObsEva (OBSV), and currently serves on the boards of Inventiva (IVA), NBE Therapeutics, Epsilon-3 Bio and Stargazer Pharmaceuticals.

Prior to her time at Novo Holdings, Nanna was part of the life science investment team at Apposite Capital, a London-based venture fund, where she participated in both primary and secondary investments, with multiple portfolio companies leading to highly successful exits for the fund, including Convergence, Ulthera and Cancer Partners UK. She also has experience from Cancer Research UK as a research analyst, and as a consultant to various biotech and healthcare venture projects during her MBA. Nanna received her PhD in Neuroscience from University College London, an MBA with distinction from University of Cambridge, and a 1st class BA from University of Oxford.

Iain D. Dukes - Non-Executive Director

Iain D. Dukes, D.Phil., is a Venture Partner with OrbiMed. Iain also serves on the Board of Lion Biotechnologies. Most recently Iain was a Senior Vice President, Business Development & Licensing Merck where he oversaw all licensing deals for Merck Research Laboratories, including external research, out-licensing, regional deals and academic alliances. Iain has more than 20 years of experience in pharmaceutical research, drug discovery, scientific and technology licensing, start-up company leadership, as well as consulting for numerous biotech and venture capital organizations. Before joining Merck, he served as vice president of External Research and Development at Amgen. He has also held positions as president and CEO of Essentialis Therapeutics and as Vice President, Scientific and Technology Licensing at GlaxoSmithKline. Iain received his D.Phil. degree from the University of Oxford where he also received a B.A. in Jurisprudence.

Management Team
Dr Ken Powell - Chairman

Prior to his current role, Ken had very extensive experience of the Biotechnology sector. In reverse order he was: Executive Chairman of Q-Chip a Cardiff, Wales based life science company developing novel delayed release formulations of drugs (merged with Midatech and the joint company listed on AIM in 2015). Founder and CEO of Arrow Therapeutics Ltd (a specialised antiviral drug discovery company acquired by Astra-Zeneca PLC for $150 million in February 2007). Professor at UCL and Deputy Director of the Wolfson Institute for Biomedical Research where he had responsibility for commercial activity including setting up five biotechnology start-up companies. He was a senior Pharmaceutical executive with the Wellcome Foundation which he decided to leave at the Wellcome/Glaxo merger. He has had a successful academic career in the UK and USA.

He is an expert virologist and has been involved in the development of multiple drugs including anti-viral compounds against herpes viruses, HIV, Hepatitis C and RSV.

 

Dr Eddy Littler - Chief Executive Officer

Eddy began his research career at the University of Leeds studying herpesvirus DNA replication. After postdoctoral research at McMaster University in Canada, he joined the Paterson Institute for Cancer Research in Manchester. Here Eddy investigated viruses and cancer including Epstein-Barr virus and Human Herpesvirus type 6. After six successful years, he joined the Wellcome Research Laboratories as Head of Herpes Virus Research. During his time at Wellcome, he became Head of the Gene Targets Group which had projects in herpesviruses, respiratory viruses, including RSV, and gene therapy of ovarian cancer. Following the acquisition of Wellcome by Glaxo he became Head of Antiviral Research at GlaxoWellcome leading teams working on hepatitis C virus, influenza virus, and respiratory syncytial virus.  

Eddy left GSK in 2000 to join Medivir as Senior Director of Lead Discovery and Head of UK Operations. While at Medivir he played a significant role in several deals, including the development and eventual out-licensing of the HCV protease inhibitor (Simeprevir) programme to Tibotec (J&J). The total value of transactions converted at Medivir was $360M.

Eddy became the Chief Executive Officer of Domainex in May 2008. He developed Domainex to become one of the UK's leading drug discovery CROs. Under his leadership, Domainex also developed a pipeline of drugs aimed at inflammation and cancer. In October 2016 Eddy joined ReViral as CEO.

 

Dr Stuart Cockerill - Chief Scientific Officer, Founder

Stuart Cockerill PhD Chief Scientific Officer, Founder Stuart was the Principal Investigator on a Wellcome Trust funded Project, on behalf of ReViral. He obtained his PhD in Organic Chemistry at the University of Leeds. After a Postdoctoral fellowship at Cornell University, he joined the GSK heritage company, the Wellcome Foundation and over the next 15 years led drug discovery projects in Pesticides, Immunology, Virology and Oncology. His key achievement was leading the erbB2 Oncology Project Team that discovered Tykerb™ for which Stuart is a named inventor. In December 2000, Stuart joined Arrow Therapeutics as Head of Chemistry and subsequently as Research Director. Stuart remained as Head of Arrow until the end of 2010. Stuart held the position of Senior Lecturer in Medicinal Chemistry at the University of Durham. His key achievements were two clinical Proof of Concept drug candidates involving novel approaches to the treatment of Respiratory Syncytial Virus and Hepatitis C Virus infection. Stuart is an author of over 70 papers, patents and book chapters.

Dr Rachel Harland - Chief Operating Officer

Dr Rachel Harland joined ReViral in 2016 from Astra-Zeneca where she had been directing a wide range of toxicology programmes. Prior to her role at AZ Rachel was Director of Toxicology for Shire Pharmaceuticals. Rachel was Development Manager at two Biotechnology companies – Arrow Therapeutics Ltd (sold to Astra-Zeneca) and Q-Chip Ltd (now Midatech and listed on the LSE) where her development strategies were a key part of the company value. Rachel spent some 10 years at Roche Products initially as a Pre-clinical Science Leader and then as a Project Manager. Rachel gained both her BSc and PhD from the University of Liverpool.

Dr Neil Mathews - Project Director, Founder

Neil has 20 years experience as a medicinal chemist in the pharma industry, across receptor, enzyme, kinase and antiviral targets. After a PhD at Imperial College and a postdoc year in Paris, Neil joined The Wellcome Foundation at Beckenham before moving to Stevenage as a group leader as it became GlaxoWellcome. At the time of the transition to GSK, Neil left to join Arrow Therapeutics where he led the Lead Optimisation group and managed the HCV projects up to and through their acquisition by AstraZeneca. Neil has a thorough understanding of the compound quality required by large pharma in-licensing groups at all stages of early development.

Max Herrmann - Chief Financial Officer

Mr Herrmann is Chief Financial Officer of ReViral Ltd and Managing Director at Stifel. He is a qualified Chartered Accountant and possesses more than 20 years of biotechnology and pharmaceutical industry experience, having held key management positions with leading development stage companies, as well as several investment banks. Mr Herrmann’s last role was as Chief Financial Officer of Silence Therapeutics plc. Prior to joining Silence, Max served as Chief Financial Officer of Intercytex Group plc, a publicly traded company focused on the emerging area of regenerative medicine. Before joining Intercytex, he spent over ten years as a sell side equity analyst, most latterly as Managing Director and Head of European Pharmaceutical and Biotechnology Research at ING. He has also held the position of Financial Controller for US based Onyx Pharmaceuticals Inc. He holds a BSc in Microbiology from the University of Kent and qualified as a Chartered Account with Arthur Andersen.

Dr Elaine Thomas - Head of Virology

Dr Elaine Thomas is an experienced virologist with a wide range of virology R&D experience. She obtained her PhD in HIV Virology at University College London.  After a post-doctoral fellowship at Harvard Medical School she joined the virology team at Arrow Therapeutics working on both RSV and HCV projects until the end of 2010.  She joined ReViral from hVivo where she was involved in a variety of pre-clinical and clinical virology studies on respiratory viruses including RSV.